KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Net Income towards Common Stockholders rose 32504.62% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 11311.16%. This contributed to the annual value of -$278.2 million for FY2024, which is 3681.73% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Net Income towards Common Stockholders of $251.1 million as of Q3 2025, which was up 32504.62% from -$66.3 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $251.1 million in Q3 2025 and a low of -$405.9 million during Q3 2022
  • In the last 5 years, Alnylam Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$174.1 million in 2023 and averaged -$135.5 million.
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Net Income towards Common Stockholders was 32504.62% (2025), while the steepest drop was 29242.7% (2025).
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Net Income towards Common Stockholders stood at -$258.5 million in 2021, then grew by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then surged by 399.76% to $251.1 million in 2025.
  • Its last three reported values are $251.1 million in Q3 2025, -$66.3 million for Q2 2025, and -$57.5 million during Q1 2025.